VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Moves Forward in Developing As-Needed Treatment for Social Anxiety Disorder

Company signs a worldwide licensing agreement with Pherin Pharmaceuticals for the development and commercialization of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder Untreated social anxiety disorder has a significant impact on a person’s overall quality of life Clinical studies support the potential of PH94B to be a superior treatment alternative for SAD due to the demonstrated rapid onset of efficacy, route of administration, as-needed dosing convenience and excellent safety profile

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need. The company recently announced (http://nnw.fm/fNN2i) that it has signed a license with Pherin Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel treatments for neuropsychiatric and neuroendocrine conditions, for exclusive worldwide rights of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder.

An estimated 15 million American adults are affected by social anxiety disorder, also called social phobia or SAD. It is the third most common psychiatric condition, following depression and substance use, and generally precedes other disorders. A person suffering from…

Read More>>

More from NetworkNewsWire

ChineseInvestors.com, Inc.’s (CIIX) CBD Biotechnology Co. Ltd. Sets December Launch for CBD Hemp-Infused Rice Wine, Sees it as ‘Sales Driver’ Net Element, Inc. (NASDAQ: NETE) to Launch Third Party Bank Processing Service in Russia DEA Decision to Remove Some Cannabidiol from Most Restrictive Class of Controlled Substances May Have Far-Reaching Impact on the CBD Market

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]